Merck to create separate cancer business to offset Keytruda patent loss

Source

In this article

Exterior view of the entrance to Merck headquarters on Feb. 05, 2024 in Rahway, New Jersey.
Spencer Platt | Getty Images

Merck said on ⁠Monday it will split its human-health ​business into ​two ​divisions, separating its blockbuster cancer franchise led by Keytruda from ⁠its non-oncology ‌medicines.

The shake-up comes as ⁠the drugmaker braces for the looming loss of exclusivity on Keytruda, ‌which accounted for nearly half of Merck's total revenue ​in 2025. Shares of the U.S. drugmaker were up 1.4% in premarket ⁠trading.

The news was first reported ‌by the Wall ‌Street Journal earlier in the day.

Keytruda, approved for several forms ⁠of cancer, recorded sales of more than $30 ⁠billion in ⁠2025 and is the best-selling prescription medicine in the ​world.

The pharma ‌major has tripled its pipeline since 2021 and has been diversifying into multiple therapeutic ​areas to bolster its portfolio.